Aleafia Health To Acquire Emblem In All-Stock Deal To Bolster Medical Marijuana Businesses

The consolidation in the cannabis industry continues as companies not just in the United States are making deals. Canada-based Aleafia Health ALEAF announced the acquisition of peer Emblem Corp EMMBF in an all-stock transaction.

What Happened

Aleafia Health said the value of the deal is C$173.2 million ($128.9 million). The company will give 0.8377 shares per each share of Emblem, which represents C$1.21 per Emblem share and a premium of 27 percent based on the closing prices of Aleafia and Emblem on the TSX Venture Exchange on Dec. 18.

After the deal is completed, Aleafia shareholders will control 59 percent of the combined company, while Emblem stockholders will keep the other 41 percent.

Cannabis investors can't miss the Benzinga Cannabis Capital Conference, the No. 1 networking event for institutional capital and the leading cannabis companies. Secure your tickets here before they run out.

Why It's Important

"Emblem's patient-focused product portfolio and strength in patient education, conversion and retention through GrowWise will be further bolstered by the patient acquisition capabilities of Aleafia's Canabo clinics," Emblem CEO Nick Dean said in a press release.

Despite the fact that Canada officially legalized marijuana two months ago, many issues remain across the country, mainly in the forms of supply shortages and bottlenecks, which many blame on the government. Joining forces in this environment could help cannabis companies weather through the current situation, while also ramping up their footprint as cannabis becomes more widely available across the country.

What's Next

Aleafia and Emblem expect that their combination will create one of the leaders in the Canadian marijuana space. The new company will have the largest national clinic network, with 40 locations across the country. In addition, the combination will allow both companies to grow 138,000 kilograms of marijuana per year.

Related Links:

Analyst: Insys To Benefit As FDA Pushes Naloxone Access

Left Sees Big Upside In Aphria, Says 'The Bidding War Is On'

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: CannabisNewsShort SellersM&AMarketsCanadaCannabis M&ACitron Research
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis is evolving – don’t get left behind!

Curious about what’s next for the industry and how to leverage California’s unique market?

Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!

Get your tickets now to secure your spot and avoid last-minute price hikes.